Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × stenoparib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 1745 Radiotherapy 1699 Cisplatin 1544 Carboplatin 1315 Gemcitabine 1212 Paclitaxel 1118 Bevacizumab 1091 Docetaxel 1061 pembrolizumab 1051 Capecitabine 1001 Oxaliplatin 987 Fluorouracil 925 Dexamethasone 828 Magnetic Resonance Spectroscopy 818 Nivolumab 790 Rituximab 783 Drug Therapy 760 Surveys and Questionnaires 755 Doxorubicin 710 Etoposide 703 Radiosurgery 692 Blood Specimen Collection 682 Irinotecan 662 Cytarabine 636 fludarabine 617 Leucovorin 581 Surgical Procedures, Operative 538 Lenalidomide 531 Biopsy 490 Radiation 489

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

The University of Texas Health Science Center at San Antonio

Phase 1/2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡